CIB3: A Potential Drug Target and Biomarker (G117286)

Target Name: CIB3

NCBI ID: G117286

CIB3

CIB3: A Potential Drug Target and Biomarker

Cysteinyl-proline synthetase (CPS) is an enzyme that plays a crucial role in the production of the protein cysteinyl-proline, which is known to be involved in various cellular processes. CPS is an enzyme that is present in many different cell types, including epithelial cells, pericytes, and immune cells. However, its function and the specific roles it plays in various cellular processes are not well understood.

Recent studies have identified CIB3, a protein that is similar to CPS, as a potential drug target and biomarker. CIB3 is expressed in many different cell types, including epithelial cells, and has been shown to play a role in various cellular processes, including cell signaling, DNA replication, and repair.

The Potential Role of CIB3 as a Drug Target

One of the potential benefits of targeting CIB3 is its ability to modulate the activity of other enzymes. For example, studies have shown that CIB3 can interact with the enzyme tyrosine aminotransferase (TAT), which is involved in the production of neurotransmitters such as dopamine. This interaction between CIB3 and TAT suggests that CIB3 may be a useful target for drugs that are designed to treat neurodegenerative diseases.

Another potential benefit of targeting CIB3 is its role in cell signaling. CIB3 has been shown to play a role in various signaling pathways, including the TGF-β pathway. This pathway is involved in cell signaling and has been implicated in various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. Targeting CIB3 may be a useful way to treat these diseases.

The Potential Role of CIB3 as a Biomarker

In addition to its potential as a drug target, CIB3 has also been identified as a potential biomarker. Studies have shown that CIB3 is expressed in various types of cancer, including breast, ovarian, and prostate cancer. This suggests that CIB3 may be a useful biomarker for these types of cancer.

CIB3 has also been shown to be involved in the production of various proteins that are involved in cancer progression. For example, studies have shown that CIB3 is involved in the production of the protein IDH1, which is involved in the production of mutated proteins that are often found in cancer cells. Targeting CIB3 may be a useful way to treat cancer.

Conclusion

In conclusion, CIB3 is a protein that is similar to CPS and has been shown to play a role in various cellular processes. The potential benefits of targeting CIB3 include its ability to modulate the activity of other enzymes and its role in cell signaling. In addition, CIB3 has also been identified as a potential biomarker for various types of cancer. Further research is needed to fully understand the role of CIB3 in these processes and to develop treatments that can effectively target it.

Protein Name: Calcium And Integrin Binding Family Member 3

Functions: Acts a an auxiliary subunit of the sensory mechanoelectrical transduction (MET) channel in hair cells (By similarity). Plays a role in regulating hair cell MET channel localization and function (By similarity)

The "CIB3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CIB3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets